Bright Minds Biosciences Inc. (DRUG)
Automate Your Wheel Strategy on DRUG
With Tiblio's Option Bot, you can configure your own wheel strategy including DRUG - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DRUG
- Rev/Share 0.0
- Book/Share 7.3165
- PB 10.4285
- Debt/Equity 0.0027
- CurrentRatio 86.5609
- ROIC -0.1426
- MktCap 540585622.0549
- FreeCF/Share -1.1133
- PFCF -68.5433
- PE -60.7784
- Debt/Assets 0.0027
- DivYield 0
- ROE -0.2081
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | DRUG | BTIG Research | -- | Buy | -- | $72 | Sept. 8, 2025 |
| Initiation | DRUG | TD Cowen | -- | Buy | -- | -- | May 13, 2025 |
| Initiation | DRUG | Chardan Capital Markets | -- | Buy | -- | $80 | May 7, 2025 |
| Initiation | DRUG | Piper Sandler | -- | Overweight | -- | $93 | Jan. 23, 2025 |
| Initiation | DRUG | Cantor Fitzgerald | -- | Overweight | -- | -- | Jan. 10, 2025 |
| Initiation | DRUG | H.C. Wainwright | -- | Buy | -- | $85 | Jan. 10, 2025 |
News
Bright Minds Biosciences Inc. (DRUG) is on the Move, Here's Why the Trend Could be Sustainable
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Bright Minds Biosciences Inc. (DRUG) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Read More
Wall Street Analysts Believe Bright Minds Biosciences Inc. (DRUG) Could Rally 81.29%: Here's is How to Trade
Published: September 18, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at an 81.3% upside potential for Bright Minds Biosciences Inc. (DRUG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Does Bright Minds Biosciences Inc. (DRUG) Have the Potential to Rally 114.07% as Wall Street Analysts Expect?
Published: September 02, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at an 114.1% upside potential for Bright Minds Biosciences Inc. (DRUG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that it will host a virtual R&D Day on Tuesday, May 20, 2025, from 10:00 am – 11:30 am ET.
Read More
About Bright Minds Biosciences Inc. (DRUG)
- IPO Date 2021-03-22
- Website https://brightmindsbio.com
- Industry Biotechnology
- CEO Ian McDonald
- Employees None